- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07677904
Tuberculosis Clinical Registry in Europe
24. juni 2026 opdateret af: Anca Vasiliu, Research Center Borstel
Tuberculosis Clinical Registry in Europe - the TBnet Registry
The TBnet registry is a multinational, prospective tuberculosis registry established by the Tuberculosis Network European Trialsgroup (TBnet e.V.) to collect and analyze long-term data from TB patients across Europe.
Its purpose is to centralize data on TB epidemiology, prevention, diagnosis, and treatment to improve care, support research, and ultimately help eliminate TB.
The registry captures risk factors, diagnostic details (e.g., microbiology, imaging, drug resistance), treatment data, side effects, outcomes, and late complications.
Studieoversigt
Status
Ikke rekrutterer endnu
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
In Western Europe, however, tuberculosis is a rare disease, and individual clinics see only small numbers of patients.
For clinical research on the epidemiology, prevention, diagnosis, and treatment of tuberculosis, it is therefore essential that patient data are collected and analyzed in a centralized manner.
This allows for the adequate inclusion of at-risk groups and studying less common forms of tuberculosis (e.g., multidrug-resistant tuberculosis, extrapulmonary tuberculosis).
Hence, the Tuberculosis Network European Trialsgroup TBnet e.V., aims to establish a tuberculosis registry in which long-term datasets from TB patients across Europe will be stored.
The findings obtained from the tuberculosis registry will make an important contribution to combating and ultimately eliminating TB.
TBnet is a pan-European clinical research network dedicated to improving the diagnosis, treatment, and prevention of tuberculosis and related mycobacterial diseases.
Founded in 2006, TBnet brings together clinicians, scientists, and public health experts from more than 30 countries.
The network has established large collaborative cohorts and conducts multicenter clinical studies, registries, and consensus projects that have shaped international TB guidelines.
The TBnet Steering Committee will serve as data access committee: Research questions/data inquiries will be submitted to the TBnet Steering Committee through a structured process on the TBnet website and are approved only after internal and external peer review (as outlined in the TBnet statutes).
Undersøgelsestype
Observationel
Tilmelding (Anslået)
1000
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiekontakt
- Navn: Anca Vasiliu, MD PhD
- Telefonnummer: +49 4537 188 8080
- E-mail: tbnetregistry@fz-borstel.de
Studiesteder
-
-
Verona
-
Negrar, Verona, Italien, 37024
- IRCCS Ospedale Sacro Cuore Don Calabria
-
Kontakt:
- Lorenzo Guglielmetti, MD PhD
- Telefonnummer: +39 0456013111
- E-mail: tbnetregistry@fz-borstel.de
-
-
-
-
Schleswig-Holstein
-
Borstel, Schleswig-Holstein, Tyskland, 23845
- Research Center Borstel, Leibniz Lung Center
-
Kontakt:
- Anca Vasiliu, MD PhD
- Telefonnummer: +49 4537 188 8080
- E-mail: tbnetregistry@fz-borstel.de
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Ingen
Prøveudtagningsmetode
Ikke-sandsynlighedsprøve
Studiebefolkning
Inpatients in tuberculosis care
Beskrivelse
Inclusion Criteria:
- Diagnosis of Tuberculosis
- Age ≥ 18 years
- Capacity to provide informed consent
- Written informed consent to participate in the study
Exclusion Criteria:
- Lack of capacity to provide informed consent
- Age < 18 years
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Kohorter og interventioner
Gruppe / kohorte |
Intervention / Behandling |
|---|---|
|
Extrapulmonary TB
Individuals affected by extrapulmonary tuberculosis
|
Prospective data collection in a clinical data registry
|
|
drug-resistant TB
Individuals affected by rifampicin- and higher-resistant tuberculosis
|
Prospective data collection in a clinical data registry
|
|
drug-susceptible TB
Individuals affected by rifampicin-susceptible tuberculosis
|
Prospective data collection in a clinical data registry
|
|
TDM
Individuals under anti-tuberculosis treatment with an indication for therapeutic drug monitoring
|
Prospective data collection in a clinical data registry
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Extrapulmonary TB: Favourable treatment outcome
Tidsramme: December 2040
|
Identification of parameters that predict/are significantly associated with favorable outcome in EPTB
|
December 2040
|
|
Drug-resistant TB: Description of treatment outcome
Tidsramme: December 2040
|
Percentage of patients cured, failed, died, under/after therapy according to WHO and TBnet outcome criteria
|
December 2040
|
|
Drug-resistant TB: Description of treatment completion
Tidsramme: December 2040
|
Percentage of patients who develop serious/severe drug-related adverse events/who have to change regimen due to drug-related adverse events
|
December 2040
|
|
Drug-susceptible TB: Mortality risk score
Tidsramme: December 2040
|
Development of a TB mortality risk score, defined by a final set of predictors and a weighted scoring system based on routine clinical, radiological, microbiological, and laboratory data.
|
December 2040
|
|
Therapeutic drug monitoring: Description of Pharmacokinetics
Tidsramme: December 2040
|
Summary of pharmacokinetic parameters: Mean max/min concentrations, number of patients that are over-/under-/correctly dosed
|
December 2040
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Anslået)
1. juli 2026
Primær færdiggørelse (Anslået)
1. december 2040
Studieafslutning (Anslået)
1. december 2040
Datoer for studieregistrering
Først indsendt
24. juni 2026
Først indsendt, der opfyldte QC-kriterier
24. juni 2026
Først opslået (Faktiske)
1. juli 2026
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
1. juli 2026
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
24. juni 2026
Sidst verificeret
1. juni 2026
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Infektioner
- Gram-positive bakterielle infektioner
- Bakterielle infektioner
- Bakterielle infektioner og mykoser
- Actinomycetales infektioner
- Mycobacterium infektioner
- Tuberkulose, Ekstrapulmonal
- Tuberkulose
- Sundhedsvæsenets kvalitet, adgang og evaluering
- Undersøgelsesteknikker
- Epidemiologiske metoder
- Evalueringsmekanismer til sundhedsvæsenet
- Sundhedskvalitet
- Folkesundhed
- Miljø og folkesundhed
- Dataindsamling
Andre undersøgelses-id-numre
- TBnet_Registry
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
INGEN
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Tuberkulose
-
Nagasaki UniversityIkke rekrutterer endnuTuberkulose | Mycobacterium Tuberculosis | LungetuberkuloserKenya
-
University Children's Hospital BaselUniversity Hospital, Geneva; University Hospital Inselspital, Berne; Kantonsspital... og andre samarbejdspartnereRekrutteringTuberkulose | Mycobacterium TuberculosisSchweiz
-
National Institute of Allergy and Infectious Diseases...AfsluttetMycobacterium TuberculosisBrasilien
-
The University of Texas Health Science Center,...National Institute of Allergy and Infectious Diseases (NIAID)AfsluttetMycobacterium TuberculosisForenede Stater, Colombia, Mexico
-
National Institute of Allergy and Infectious Diseases...Aktiv, ikke rekrutterendeOpportunistiske infektioner | Mycobacterium Tuberculosis | Ikke-tuberkuløse mykobakterierThailand, Kina, Taiwan
-
Johns Hopkins UniversityAfsluttetMycobacterium TuberculosisForenede Stater
-
National Institute of Allergy and Infectious Diseases...Afsluttet
-
Assistance Publique - Hôpitaux de ParisViatris Inc.Ikke rekrutterer endnuAntibiotikaresistens | Mycobacterium Tuberculosis | MDR-TB | Tuberkulose Multi Drug Resistant ActiveFrankrig
-
National Institute of Allergy and Infectious Diseases...Afsluttet
-
François SpertiniUniversity of OxfordAfsluttetTuberkulose | Mycobacterium Tuberculosis, Beskyttelse modSchweiz
Kliniske forsøg med data collection
-
Acorai ABAfsluttetHjertefejlForenede Stater, Sverige, Det Forenede Kongerige, Canada, Danmark, Belgien
-
The Hong Kong Polytechnic UniversityLogistics and Supply Chain MultiTech R&D Centre, Hong KongRekrutteringSunde mandlige og kvindelige emnerHong Kong
-
Memorial Sloan Kettering Cancer CenterAfsluttetProstatakræftForenede Stater
-
Marmara UniversityAfsluttetCerebral Parese | Brachial Plexus PareseKalkun
-
Centro Hospitalar do PortoEIT Health; Promptly HealthAfsluttet
-
Midwest Heart & Vascular SpecialistsRekrutteringAL Amyloidose | Amyloid | Hjerte amyloidose | Amyloidose Hjerte | Systemisk amyloidose | ATTR Amyloidose vildtype | Infiltrativ kardiomyopati, amyloidForenede Stater
-
Terumo BCTAfsluttetEnhedsvalidering af in-vivo ydeevneForenede Stater
-
Bettina MittendorferRekrutteringHjertefejl | Diabetes | Hyperparathyroidisme | Sarkopeni | Osteoporose | Iskæmisk hjertesygdom | Kakeksi | Osteopeni | Hypoparathyroidisme | Cystisk fibrose (CF) | Aterosklerotisk sygdom | Kronisk nyresygdom (CKD) | Fedme og fedme-relaterede medicinske tilstande | MOSEForenede Stater
-
Massachusetts General HospitalRekruttering
-
University of FloridaTilmelding efter invitation